Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Research Chairs

McGill University

$200,000.00

Bioprocessing of Viral Vectors and Vaccines

FY 2024-25

Summary
The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering. - Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines. - Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases. Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.
Program
Canada Research Chairs
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
CRC-2021-00032
Name nom
Kamen, Amine
Department département
Bioengineering - McGill University
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2021
Award amount
200000
Program id
CRC
Program name en
Canada Research Chairs
Program name fr
Chaires de recherche du Canada
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
9998
Committee name en
Canada Research Chair Selection Committee
Committee name fr
Comité de sélection des Chaires de recherche du Canada
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Field of research list codes
RDF2070199
Field of research list names en
Medical and biomedical engineering, n.e.c.
Field of research list names fr
Génie médical et biomédical, n.c.a.
Socioeconomic objective list codes
RDS10699
Socioeconomic objective list names en
Industrial production and technology, n.e.c.
Socioeconomic objective list names fr
Production et technologie industrielles, n.c.a.
Application title
Bioprocessing of Viral Vectors and Vaccines
Keywords
Bioprocess Engineering; Cell Culture Engineering; Viral Vaccines; Viral Vectors for Gene and Cell Therapy; System Biology; Biomanufacturing; Process Analytical Technology; Data Sciences
Application summary
The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering. - Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines. - Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases. Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.
McGill University - $200,000 Grant (2024-25) | Canada Spends